<?xml version='1.0' encoding='utf-8'?>
<document id="26857335"><sentence text="Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study."><entity charOffset="32-42" id="DDI-PubMed.26857335.s1.e0" text="atazanavir" /><entity charOffset="63-92" id="DDI-PubMed.26857335.s1.e1" text="tenofovir disoproxil fumarate" /><entity charOffset="97-107" id="DDI-PubMed.26857335.s1.e2" text="lamivudine" /><pair ddi="false" e1="DDI-PubMed.26857335.s1.e0" e2="DDI-PubMed.26857335.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26857335.s1.e0" e2="DDI-PubMed.26857335.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26857335.s1.e0" e2="DDI-PubMed.26857335.s1.e2" /><pair ddi="false" e1="DDI-PubMed.26857335.s1.e1" e2="DDI-PubMed.26857335.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26857335.s1.e1" e2="DDI-PubMed.26857335.s1.e2" /></sentence><sentence text="Treatment response to switch regimens containing unboosted atazanavir and tenofovir disoproxil fumarate (TDF)/lamivudine guided by therapeutic drug monitoring in human immunodeficiency virus-infected patients is rarely investigated"><entity charOffset="59-69" id="DDI-PubMed.26857335.s2.e0" text="atazanavir" /><entity charOffset="74-103" id="DDI-PubMed.26857335.s2.e1" text="tenofovir disoproxil fumarate" /><entity charOffset="105-108" id="DDI-PubMed.26857335.s2.e2" text="TDF" /><entity charOffset="110-120" id="DDI-PubMed.26857335.s2.e3" text="lamivudine" /><pair ddi="false" e1="DDI-PubMed.26857335.s2.e0" e2="DDI-PubMed.26857335.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26857335.s2.e0" e2="DDI-PubMed.26857335.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26857335.s2.e0" e2="DDI-PubMed.26857335.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26857335.s2.e0" e2="DDI-PubMed.26857335.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26857335.s2.e1" e2="DDI-PubMed.26857335.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26857335.s2.e1" e2="DDI-PubMed.26857335.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26857335.s2.e1" e2="DDI-PubMed.26857335.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26857335.s2.e2" e2="DDI-PubMed.26857335.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26857335.s2.e2" e2="DDI-PubMed.26857335.s2.e3" /></sentence><sentence text="" /><sentence text="Consecutive patients with plasma human immunodeficiency virus RNA load &lt; 200 copies/mL switching to unboosted atazanavir plus zidovudine-lamivudine (coformulated), abacavir-lamivudine (coformulated), or TDF/lamivudine &gt; 3 months were included for determinations of treatment response, plasma atazanavir concentrations, and single-nucleotide polymorphisms of MDR1, PXR, and UGT1A1 genes from 2010 to 2014"><entity charOffset="110-120" id="DDI-PubMed.26857335.s4.e0" text="atazanavir" /><entity charOffset="126-136" id="DDI-PubMed.26857335.s4.e1" text="zidovudine" /><entity charOffset="137-147" id="DDI-PubMed.26857335.s4.e2" text="lamivudine" /><entity charOffset="164-172" id="DDI-PubMed.26857335.s4.e3" text="abacavir" /><entity charOffset="173-183" id="DDI-PubMed.26857335.s4.e4" text="lamivudine" /><entity charOffset="203-206" id="DDI-PubMed.26857335.s4.e5" text="TDF" /><entity charOffset="207-217" id="DDI-PubMed.26857335.s4.e6" text="lamivudine" /><entity charOffset="292-302" id="DDI-PubMed.26857335.s4.e7" text="atazanavir" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e0" e2="DDI-PubMed.26857335.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e0" e2="DDI-PubMed.26857335.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e0" e2="DDI-PubMed.26857335.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e0" e2="DDI-PubMed.26857335.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e0" e2="DDI-PubMed.26857335.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e0" e2="DDI-PubMed.26857335.s4.e5" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e0" e2="DDI-PubMed.26857335.s4.e6" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e0" e2="DDI-PubMed.26857335.s4.e7" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e1" e2="DDI-PubMed.26857335.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e1" e2="DDI-PubMed.26857335.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e1" e2="DDI-PubMed.26857335.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e1" e2="DDI-PubMed.26857335.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e1" e2="DDI-PubMed.26857335.s4.e5" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e1" e2="DDI-PubMed.26857335.s4.e6" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e1" e2="DDI-PubMed.26857335.s4.e7" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e2" e2="DDI-PubMed.26857335.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e2" e2="DDI-PubMed.26857335.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e2" e2="DDI-PubMed.26857335.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e2" e2="DDI-PubMed.26857335.s4.e5" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e2" e2="DDI-PubMed.26857335.s4.e6" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e2" e2="DDI-PubMed.26857335.s4.e7" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e3" e2="DDI-PubMed.26857335.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e3" e2="DDI-PubMed.26857335.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e3" e2="DDI-PubMed.26857335.s4.e5" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e3" e2="DDI-PubMed.26857335.s4.e6" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e3" e2="DDI-PubMed.26857335.s4.e7" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e4" e2="DDI-PubMed.26857335.s4.e4" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e4" e2="DDI-PubMed.26857335.s4.e5" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e4" e2="DDI-PubMed.26857335.s4.e6" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e4" e2="DDI-PubMed.26857335.s4.e7" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e5" e2="DDI-PubMed.26857335.s4.e5" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e5" e2="DDI-PubMed.26857335.s4.e6" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e5" e2="DDI-PubMed.26857335.s4.e7" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e6" e2="DDI-PubMed.26857335.s4.e6" /><pair ddi="false" e1="DDI-PubMed.26857335.s4.e6" e2="DDI-PubMed.26857335.s4.e7" /></sentence><sentence text=" Treatment failure was defined as either discontinuation of atazanavir for any reason or plasma viral load ≥ 200 copies/mL within 96 weeks"><entity charOffset="60-70" id="DDI-PubMed.26857335.s5.e0" text="atazanavir" /></sentence><sentence text="" /><sentence text="During the study period, 128 patients switched to unboosted atazanavir with TDF/lamivudine (TDF group) and 186 patients switched to unboosted atazanavir with two other nucleoside reverse-transcriptase inhibitors (non-TDF group)"><entity charOffset="60-70" id="DDI-PubMed.26857335.s7.e0" text="atazanavir" /><entity charOffset="76-79" id="DDI-PubMed.26857335.s7.e1" text="TDF" /><entity charOffset="80-90" id="DDI-PubMed.26857335.s7.e2" text="lamivudine" /><entity charOffset="92-95" id="DDI-PubMed.26857335.s7.e3" text="TDF" /><entity charOffset="142-152" id="DDI-PubMed.26857335.s7.e4" text="atazanavir" /><entity charOffset="217-226" id="DDI-PubMed.26857335.s7.e5" text="TDF" /><pair ddi="false" e1="DDI-PubMed.26857335.s7.e0" e2="DDI-PubMed.26857335.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26857335.s7.e0" e2="DDI-PubMed.26857335.s7.e1" /><pair ddi="false" e1="DDI-PubMed.26857335.s7.e0" e2="DDI-PubMed.26857335.s7.e2" /><pair ddi="false" e1="DDI-PubMed.26857335.s7.e0" e2="DDI-PubMed.26857335.s7.e3" /><pair ddi="false" e1="DDI-PubMed.26857335.s7.e0" e2="DDI-PubMed.26857335.s7.e4" /><pair ddi="false" e1="DDI-PubMed.26857335.s7.e0" e2="DDI-PubMed.26857335.s7.e5" /><pair ddi="false" e1="DDI-PubMed.26857335.s7.e1" e2="DDI-PubMed.26857335.s7.e1" /><pair ddi="false" e1="DDI-PubMed.26857335.s7.e1" e2="DDI-PubMed.26857335.s7.e2" /><pair ddi="false" e1="DDI-PubMed.26857335.s7.e1" e2="DDI-PubMed.26857335.s7.e3" /><pair ddi="false" e1="DDI-PubMed.26857335.s7.e1" e2="DDI-PubMed.26857335.s7.e4" /><pair ddi="false" e1="DDI-PubMed.26857335.s7.e1" e2="DDI-PubMed.26857335.s7.e5" /><pair ddi="false" e1="DDI-PubMed.26857335.s7.e2" e2="DDI-PubMed.26857335.s7.e2" /><pair ddi="false" e1="DDI-PubMed.26857335.s7.e2" e2="DDI-PubMed.26857335.s7.e3" /><pair ddi="false" e1="DDI-PubMed.26857335.s7.e2" e2="DDI-PubMed.26857335.s7.e4" /><pair ddi="false" e1="DDI-PubMed.26857335.s7.e2" e2="DDI-PubMed.26857335.s7.e5" /><pair ddi="false" e1="DDI-PubMed.26857335.s7.e3" e2="DDI-PubMed.26857335.s7.e3" /><pair ddi="false" e1="DDI-PubMed.26857335.s7.e3" e2="DDI-PubMed.26857335.s7.e4" /><pair ddi="false" e1="DDI-PubMed.26857335.s7.e3" e2="DDI-PubMed.26857335.s7.e5" /><pair ddi="false" e1="DDI-PubMed.26857335.s7.e4" e2="DDI-PubMed.26857335.s7.e4" /><pair ddi="false" e1="DDI-PubMed.26857335.s7.e4" e2="DDI-PubMed.26857335.s7.e5" /></sentence><sentence text=" There were no statistically significant differences in the distributions of single-nucleotide polymorphisms of MDR1 (2677 and 3435), PXR genotypes (63396), and UGT1A1*28 between the two groups" /><sentence text=" Recommended plasma atazanavir concentrations were achieved in 83"><entity charOffset="20-30" id="DDI-PubMed.26857335.s9.e0" text="atazanavir" /></sentence><sentence text="5% and 64" /><sentence text="9% of the TDF group and non-TDF group, respectively (p &lt; 0"><entity charOffset="10-13" id="DDI-PubMed.26857335.s11.e0" text="TDF" /><entity charOffset="28-30" id="DDI-PubMed.26857335.s11.e1" text="TDF" /><pair ddi="false" e1="DDI-PubMed.26857335.s11.e0" e2="DDI-PubMed.26857335.s11.e0" /><pair ddi="false" e1="DDI-PubMed.26857335.s11.e0" e2="DDI-PubMed.26857335.s11.e1" /></sentence><sentence text="01)" /><sentence text=" After a median follow-up duration of 96" /><sentence text="0 weeks, treatment failure occurred in 19 (14" /><sentence text="9%) and 34 (18" /><sentence text="3%) patients in the TDF group and non-TDF group, respectively (p = 0"><entity charOffset="20-22" id="DDI-PubMed.26857335.s16.e0" text="TDF" /><entity charOffset="38-40" id="DDI-PubMed.26857335.s16.e1" text="TDF" /><pair ddi="false" e1="DDI-PubMed.26857335.s16.e0" e2="DDI-PubMed.26857335.s16.e0" /><pair ddi="false" e1="DDI-PubMed.26857335.s16.e0" e2="DDI-PubMed.26857335.s16.e1" /></sentence><sentence text="60)" /><sentence text=" Low-level viremia (40-200 copies/mL) before switch (adjusted hazard ratio, 2" /><sentence text="12; 95% confidence interval, 1" /><sentence text="12-4" /><sentence text="01) and without therapeutic drug monitoring (adjusted hazard ratio, 2" /><sentence text="08; 95% confidence interval, 1" /><sentence text="16-3" /><sentence text="73) were risk factors for treatment failure" /><sentence text="" /><sentence text="Switch to unboosted atazanavir with TDF/lamivudine achieves a similar treatment response to that with two other nucleoside reverse-transcriptase inhibitors in patients achieving virological suppression with the guidance of therapeutic drug monitoring"><entity charOffset="20-30" id="DDI-PubMed.26857335.s26.e0" text="atazanavir" /><entity charOffset="36-39" id="DDI-PubMed.26857335.s26.e1" text="TDF" /><entity charOffset="40-50" id="DDI-PubMed.26857335.s26.e2" text="lamivudine" /><pair ddi="false" e1="DDI-PubMed.26857335.s26.e0" e2="DDI-PubMed.26857335.s26.e0" /><pair ddi="false" e1="DDI-PubMed.26857335.s26.e0" e2="DDI-PubMed.26857335.s26.e1" /><pair ddi="false" e1="DDI-PubMed.26857335.s26.e0" e2="DDI-PubMed.26857335.s26.e2" /><pair ddi="false" e1="DDI-PubMed.26857335.s26.e1" e2="DDI-PubMed.26857335.s26.e1" /><pair ddi="false" e1="DDI-PubMed.26857335.s26.e1" e2="DDI-PubMed.26857335.s26.e2" /></sentence><sentence text="" /></document>